Samuel O'Brient

Samuel O'Brient

Expertise: Global Financial Markets, Macroeconomics and Geopolitics

Education: BA, Economics & Political Science, Sarah Lawrence College; MSc, International Politics, Trinity College Dublin

Awards & Accomplishments: Published in Curlew Quarterly. Quoted in Forbes. Interviewed by Foreign Policy.

About Samuel
Samuel O’Brient is a Reporter for InvestorPlace, where his work focuses primarily on financial markets, global economic trends, and public policy. O’Brient writes a weekly column on recent political news that investors should be following.

From his early days at InvestorPlace, O’Brient found himself drawn to the booming world of electric vehicles and green energy. His coverage of mining and other battery components has made him an expert source for industry publications. During his early years as an Economic Policy Analyst at U.S. Resist News, he gained expertise in international trade as the U.S.-China trade war dominated headlines. This in-depth research and analysis experience helped strengthen his prowess in all things political economy. O’Brient brings this expertise to work with him every day, thoughtfully analyzing how the daily happenings on the Capitol trickle down to Wall Street… and how retail investors can take action to profit.

An experienced journalist, editor, and economic policy analyst, O’Brient has spent his career guided by a deep passion for economic theory and policy. As a financial blogger on TipRanks, he has received 4.6 stars and is ranked in the top 10% of stock pickers.

O’Brient’s work on economic and tech policy has been curated by popular outlets Marker, OneZero and Gen.

He can be reached on LinkedIn and Muck Rack.

Recent Articles

BYND Stock Sinks as Mizuho Downgrades Beyond Meat

Another Wall Street analyst has downgraded Beyond Meat, sending shares down. Here's why BYND stock is likely to keep falling.

UAW Expands Strike to Ford’s Kentucky Plant. What It Means for F Stock.

The UAW strike is about to include one of Ford's Kentucky plants. Here's what this development could mean for F stock.

TPST Stock: 7 Things to Know About Tempest Therapeutics

Are you curious about the recent surge from Tempest Therapeutics? Here's a closer look at this company and at TPST stock.

3 Clean Energy Stocks that Can Survive Sky-High Interest Rates

Looking for clean energy stocks that can bounce back from high interest rates? Here are three dynamic leaders in the space.

Ozempic Alert: New Trial Causes DaVita (DVA) Stock to Plunge 20%

Ozempic may be able to treat kidney disease. This news has sent competitor DaVita into a tailspin as DVA stock plunges.